New hope for advanced breast cancer: early trial of LY3484356 in chinese patients
NCT ID NCT05509790
First seen Apr 18, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This early-phase study tests a new drug called LY3484356 in Chinese patients with a specific type of advanced breast cancer (ER+/HER2-). The main goal is to see how the drug moves through the body and how safe it is. Researchers will also check if the drug can shrink tumors. The study involves 17 participants and lasts up to 28 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 201315, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
The Third Hospital of Nanchang
Nanchang, Jiangxi, 330025, China
-
Wannan Medical College Yijishan Hospital
Wuhu, Anhui, 241001, China
Conditions
Explore the condition pages connected to this study.